Diabetic eye disease: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

• All targets
• VEGF 19
• GLP-1 1
• NRF2 0
• NLRP3 1
• AMPK 0
• AKT 0
• SGLT2 1
• HIF-1 0
• PPAR 0
• PI3K 0
• mTOR 0
• STAT3 0
• MAPK 0
• STING 0
• SIRT1 0
• ERK 0
• GPX4 0
• IL-1 0
• TLR4 0
• YAP 0
• ACE2 0
• CTNNB1 0
• HMGB1 0
• IL-6 1
• MMP-9 0
• TNF 0
• TP53 0
• ANGPTL3 0
• BDNF 0
• CXCR4 0
• FTO 0
• GIP 0
• HDAC 0
• IL-17 0
• JAK 0
• MEK 0
• PDGFR 0
• PINK1 0
• APOE 0
• AQP4 0
• BAP1 0
• BCL-2 0
• CCR5 0
• CD40 0
• CDK4/6 0
• CDKN2A 0
• COX-2 0
• DPP-4 0
• EGFR 0
• FAK 0
• G6PD 0
• IL-15 0
• IL-4 0
• JNK 0
• MDM2 0
• METTL3 0
• MYC 0
• NMDA 0
• RPGR 0
• TDP-43 0

EU-13 is a filter, not a ranking: it only narrows the list.

24 of 200+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Withdrawn

  Intranasal Delivery of Octreotide for Treatment of Diabetic Macular Edema

  NCT06881888· University of Alabama at Birmingham· Updated 13 Oct 2026

  “Project terminated due to loss of sponsor funding following the dissolution of AMD Opti.”Registry text, quoted unchanged. Source

• Withdrawn

  Integrative Liver-Targeted Therapy for Diabetic Macular Edema: Using "Tauroursodeoxycholate" or Traditional Chinese Medicine.

  NCT07457632· University of Alabama at Birmingham· Updated 9 Oct 2026

  “The study was terminated due to additional regulatory requirements that could not be completed within the established academic timeline. As a result, continuation of the study was not feasible.”Registry text, quoted unchanged. Source

• Withdrawn

  A Study to Assess the Use of Artificial Intellignce to Predict Eye Treatment Changes in Adult Participants With Diabetic Macular Edema

  NCT07604545· AbbVie· Updated 28 Aug 2026

  “Company Decision”Registry text, quoted unchanged. Source

• Terminated

  Evaluation of NeoRetina Artificial Intelligence Algorithm for the Screening of Diabetic Retinopathy at the CHUM

  NCT04699864· Centre hospitalier de l'Université de Montréal (CHUM)· Updated 8 Jul 2026

  “logistical constraints”Registry text, quoted unchanged. Source

• Withdrawn

  Eye Health Intervention Study in Upper Manhattan

  NCT06112431· Columbia University· Updated 29 May 2026

  “Lack of funding”Registry text, quoted unchanged. Source

• Terminated

  A Study of Avoralstat In Participants With Diabetic Macular Edema

  NCT07228559· BioCryst Pharmaceuticals· Updated 11 May 2026

  “Strategic decision”Registry text, quoted unchanged. Source

• Terminated

  Evaluation of K9 in Subjects With Diabetic Macular Edema (DME)

  NCT06781255· Michelle Abou-Jaoude· Updated 6 Apr 2026

  “Low recruitment outcome”Registry text, quoted unchanged. Source

• Withdrawn

  UNITY VCS Vitreoretinal Surgery

  NCT07054281· Alcon Research· Updated 12 Dec 2025

  “Sponsor's business decision based on strategic shifts”Registry text, quoted unchanged. Source

• Terminated

  A Phase 2 Study of Intravitreal AVD-104 in Diabetic Macular Edema

  NCT06181227· Aviceda Therapeutics, Inc.· Updated 14 Jul 2025

  “The trial was stopped early due to insufficient study drug supply and study funding constraints”Registry text, quoted unchanged. Source

• Terminated

  Aqueous Biomarker Levels in Diabetic Retinopathy and Diabetic Macular Edema

  NCT05333055· Greater Houston Retina Research· Updated 24 Jan 2025

  “Dissolution of the ophthalmology department”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• Clinical Study to Compare Efficacy and Safety of AVT29 and Eylea HD in Participants with Diabetic Macular Edema

  2025-522231-34-00· Alvotech Swiss AG· Source

• Implementing AI-based Glaucoma Screening Within Federally Qualified Health Centers

  NCT06629649· University of Alabama at Birmingham· Source

• Pivotal Trial of Automated Artificial Intelligence (AI) Based System for Early Diagnosis of Diabetic Retinopathy

  NCT07151001· iHealthScreen Inc· Source

• Long-Term Follow-Up Study of RGX-314 Administered in the Suprachoroidal Space for Participants With and Without Diabetic Retinopathy

  NCT05296447· AbbVie· Source

• Video-based Patient Education Intervention for Diabetic Eye Screening in Latinx Communities

  NCT06257082· University of Wisconsin, Madison· Source

• A Phase 3 Trial for Intravitreal Injection of 4D-150 in Adults With Diabetic Macular Edema (DME).

  NCT07867080· 4D Molecular Therapeutics· Source

• A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-004)

  NCT07705555· Merck Sharp & Dohme LLC· Source

• A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-005)

  NCT07705607· Merck Sharp & Dohme LLC· Source

• Surabgene Lomparvovec Administered in the Suprachoroidal Space in Adult Participants With Diabetic Retinopathy Without Center-Involved Diabetic Macular Edema

  NCT07592273· AbbVie· Source

• A Study to Test Whether BI 764524 Helps People With an Eye Condition Called Diabetic Retinopathy

  NCT06321302· Boehringer Ingelheim· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 15
• Organoids 2
• Mendelian Randomization Analysis 26
• CRISPR-Cas Systems 4
• Gene Expression Profiling 34
• Sequence Analysis, RNA 3
• Exome Sequencing 2
• Proteomics 30
• Metabolomics 15
• Mass Spectrometry 2
• Flow Cytometry 5
• Immunohistochemistry 13
• Liquid Biopsy 1
• Xenograft Model Antitumor Assays 1
• Positron-Emission Tomography 1
• Magnetic Resonance Imaging 4
• Machine Learning 49
• Deep Learning 73
• Cohort Studies 47
• Genome-Wide Association Study 22

See which targets of this disease your abstract mentions, and go to the people working on them.